| Molecular formula | C32H40N4O3 |
|---|
| Molecular weight | 528.7 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 9810101 |
|---|
Tabimorelin is a synthetic compound studied in early research settings rather than approved medical practice. This profile summarizes what is known about its chemical identity and its footprint in the clinical trial registry.
What tabimorelin is
Tabimorelin is a small molecule with the molecular formula C32H40N4O3 and a molecular weight of approximately 528.7 g/mol. Its structure includes multiple aromatic rings and amide linkages, consistent with peptide-like research compounds. No FDA-approved drug label exists for tabimorelin, and it is not sold as an approved medication under any brand name. It remains classified as an unapproved research compound, and any use outside a controlled research setting is not supported by regulatory review.
Trial footprint
The clinical trial registry lists no registered studies for tabimorelin at this time. This means there is no available trial data, sample study, or phase information to summarize for this compound. Its research record, based on public registries, is currently empty.
FAQ
Tabimorelin is a synthetic small molecule compound with the molecular formula C32H40N4O3. It is classified as an unapproved research compound rather than an approved medication. No FDA label or approved indication exists for it.
No. Tabimorelin has no FDA-approved label, no approved brand name, and no approved medical indication. It is currently categorized only as an unapproved research compound.
Public clinical trial registries currently show no registered studies for tabimorelin. This means there is no trial phase, enrollment, or outcome data available to reference for this compound.
Tabimorelin has a molecular weight of about 528.7 g/mol and a formula of C32H40N4O3. Its structure contains aromatic ring systems connected through amide bonds, a pattern common among peptide-related research molecules.
No adverse event reports or side effect data are currently available for tabimorelin in public safety databases. Because it lacks an approved label and clinical trial history, no established safety profile exists yet.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-03